2020 Annual Meeting | C220 - Cannabis Update in Neurology

Date Thursday 04/30/20

Time 07:00 AM - 09:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Anup D. Patel, MD, FAAN

Topic(s) General Neurology

Learning Objectives Participants should be able to understand the updated data around medical cannabis products in epilepsy; determine what a vernacular cannabis product is compared to pharmaceutical products; and learn about studies performed using medical cannabis in neurology.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Event Timeline
07:00 AM - 07:10 AM	Introduction	Introduction Anup D. Patel, MD, FAAN
07:10 AM - 07:40 AM	Speaker	Update on Use of Medical Cannabis in Epilepsy M. S. Perry, MD
07:40 AM - 08:10 AM	Speaker	Use of Vernacular Cannabis and Other Cannabis Products in Neurology Anup D. Patel, MD, FAAN
08:10 AM - 08:40 AM	Speaker	Incorporating Medical Cannabis into Clinical Practice Jennifer W. McVige, MD, FAAN
08:40 AM - 09:00 AM	Q&A	Questions and Answers

Faculty Disclosures
Anup D. Patel, MD, FAAN	The institution of Dr. Patel has received research support from PCORI. Dr. Patel has received personal compensation in the range of $5,000-$9,999 for serving as a Webinar Development with Medscape. Dr. Patel has a non-compensated relationship as a Chair Quality Committee with AAN that is relevant to AAN interests or activities. Dr. Patel has a non-compensated relationship as a Committee Member with Child Neurology Society that is relevant to AAN interests or activities. Dr. Patel has a non-compensated relationship as a Board of Directors - member with AAN Institute that is relevant to AAN interests or activities.
M. S. Perry, MD	Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for stoke therapeutics. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Marinus. Dr. Perry has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for jazz pharmaceuticals. Dr. Perry has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for pyros. Dr. Perry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke Therapeutics. Dr. Perry has stock in Praxis Precision Medicine. Dr. Perry has stock in Longboard Pharmaceuticals. Dr. Perry has stock in Rapport. Dr. Perry has a non-compensated relationship as a president elect with child neurology foundation that is relevant to AAN interests or activities. Dr. Perry has a non-compensated relationship as a President with Pediatric Epilepsy Research Consortium that is relevant to AAN interests or activities.
Jennifer W. McVige, MD, FAAN	Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/AbbVie. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. The institution of Dr. McVige has received research support from Amgen. The institution of Dr. McVige has received research support from Eli Lily. The institution of Dr. McVige has received research support from Biohaven. The institution of Dr. McVige has received research support from Lundbeck. The institution of Dr. McVige has received research support from Dent Family Foundation. Dr. McVige has a non-compensated relationship as a Neurology Board with UCNS that is relevant to AAN interests or activities. Dr. McVige has a non-compensated relationship as a Board Exam Board Member with ABPN that is relevant to AAN interests or activities.

��ɫ��

��ɫ��